Who owns CRISPR-Cas9 in Europe?

Recent developments in the prosecution of the CRISPR-Cas9 patent in Europe highlight the differences between the intellectual property regimes of Europe and the United States.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature biotechnology 2014-12, Vol.32 (12), p.1194-1196
1. Verfasser:	Kupecz, András
Format:	Artikel
Sprache:	eng
Schlagworte:	631/154/2426/1984 631/208/200 706/648/270 Agriculture Bioinformatics Biomedical and Life Sciences Biomedical Engineering/Biotechnology Biomedicine Biotechnology CRISPR-Cas Systems Europe Genetic engineering Genome, Human Genomes Humans Intellectual Property Laws, regulations and rules Life Sciences Patent law Patents as Topic Proteins United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Recent developments in the prosecution of the CRISPR-Cas9 patent in Europe highlight the differences between the intellectual property regimes of Europe and the United States.
ISSN:	1087-0156 1546-1696
DOI:	10.1038/nbt.3086